{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:50:18Z","timestamp":1791546618484,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11095-017-2218-z","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T15:01:30Z","timestamp":1499353290000},"page":"2557-2567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data"],"prefix":"10.1007","volume":"34","author":[{"given":"Therese","family":"Ericsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Frid\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"K\u00e4rrman-M\u00e5rdh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Dainty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Grime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"issue":"5","key":"2218_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/clpt.2014.27","volume":"95","author":"P Backman","year":"2014","unstructured":"Backman P, Adelmann H, Petersson G, Jones CB. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Ther. 2014;95(5):509\u201320.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2218_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2174\/138920012800166571","volume":"13","author":"AE Cooper","year":"2012","unstructured":"Cooper AE, Ferguson D, Grime K. Optimisation of DMPK by the inhaled route: challenges and approaches. Curr Drug Metab. 2012;13(4):457\u201373.","journal-title":"Curr Drug Metab"},{"issue":"6","key":"2218_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd4309","volume":"13","author":"D Cook","year":"2014","unstructured":"Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419\u201331.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2218_CR4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1007\/s11095-005-5882-3","volume":"22","author":"M Danhof","year":"2005","unstructured":"Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res. 2005;22(9):1432\u20137.","journal-title":"Pharm Res"},{"issue":"12","key":"2218_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nrd3287","volume":"9","author":"DA Smith","year":"2010","unstructured":"Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929\u201339.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2218_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2174\/138920007780866799","volume":"8","author":"DF McGinnity","year":"2007","unstructured":"McGinnity DF, Collington J, Austin RP, Riley RJ. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab. 2007;8(5):463\u201379.","journal-title":"Curr Drug Metab"},{"issue":"2","key":"2218_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1021\/acs.molpharmaceut.5b00840","volume":"13","author":"KM Page","year":"2016","unstructured":"Page KM. Validation of early human dose prediction: a key metric for compound progression in drug discovery. Mol Pharm. 2016;13(2):609\u201320.","journal-title":"Mol Pharm"},{"issue":"12","key":"2218_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00228-001-0405-6","volume":"57","author":"BG Reigner","year":"2002","unstructured":"Reigner BG, Blesch KS. Estimating the starting dose for entry into humans: principles and practice. Eur J Clin Pharmacol. 2002;57(12):835\u201345.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"2218_CR9","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1517\/17425240903241788","volume":"6","author":"CA Fernandes","year":"2009","unstructured":"Fernandes CA, Vanbever R. Preclinical models for pulmonary drug delivery. Expert Opin Drug Deliv. 2009;6(11):1231\u201345.","journal-title":"Expert Opin Drug Deliv"},{"issue":"7","key":"2218_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/00912709922008281","volume":"39","author":"S Rohatagi","year":"1999","unstructured":"Rohatagi S, Rhodes GR, Chaikin P. Absolute oral versus inhaled bioavailability: significance for inhaled drugs with special reference to inhaled glucocorticoids. J Clin Pharmacol. 1999;39(7):661\u20133.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2218_CR11","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.4049\/jimmunol.168.6.3004","volume":"168","author":"E-B Haddad","year":"2002","unstructured":"Haddad E-B, Underwood SL, Dabrowski D, Birrel MA, McCluskie K, Battram CH, et al. Critical role for T cells in sephadex-induced airway inflammation: pharmacological and immunological characterization and molecular biomarker identification. J Immunol. 2002;168(6):3004\u201316.","journal-title":"J Immunol"},{"issue":"Pt 1","key":"2218_CR12","first-page":"3","volume":"4","author":"OG Raab","year":"1975","unstructured":"Raab OG, Yeh HC, Newton GJ, Phalen RF, Velasquez DJ. Deposition of inhaled monodisperse aerosols in small rodents. Inhaled Part. 1975;4(Pt 1):3\u201321.","journal-title":"Inhaled Part"},{"key":"2218_CR13","unstructured":"US Food and Drug Administration. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005. Access December 2016. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/UCM078932.pdf ."},{"key":"2218_CR14","first-page":"307","volume":"32","author":"DG Altman","year":"1983","unstructured":"Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. J R Stat Soc Ser D (The Statistician). 1983;32:307\u201317.","journal-title":"J R Stat Soc Ser D (The Statistician)"},{"issue":"3","key":"2218_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/sj.bjp.0706724","volume":"148","author":"G Villetti","year":"2006","unstructured":"Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Harrison S, Gigli PM, et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol. 2006;148(3):291\u20138.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"2218_CR16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1183\/09031936.98.11030583","volume":"11","author":"M Molimard","year":"1998","unstructured":"Molimard M, Naline E, Zhang Y, Le Gros V, Begaud B, Advenier C. Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J. 1998;11(3):583\u20138.","journal-title":"Eur Respir J"},{"issue":"4","key":"2218_CR17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1021\/ml4005232","volume":"5","author":"MJ Stocks","year":"2014","unstructured":"Stocks MJ, Alcaraz L, Bailey A, Bonnert R, Cadogan E, Christie J, et al. Discovery of AZD3199, an inhaled ultralong acting beta2 receptor agonist with rapid onset of action. ACS Med Chem Lett. 2014;5(4):416\u201321.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2218_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1124\/jpet.103.059592","volume":"309","author":"M Stoeck","year":"2004","unstructured":"Stoeck M, Riedel R, Hochhaus G, Hafner D, Masso JM, Schmidt B, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther. 2004;309(1):249\u201358.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"2218_CR19","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1021\/acs.molpharmaceut.5b00221","volume":"12","author":"M Rohrschneider","year":"2015","unstructured":"Rohrschneider M, Bhagwat S, Krampe R, Michler V, Breitkreutz J, Hochhaus G. Evaluation of the transwell system for characterization of dissolution behavior of inhalation drugs: effects of membrane and surfactant. Mol Pharm. 2015;12(8):2618\u201324.","journal-title":"Mol Pharm"},{"issue":"1","key":"2218_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1015765201129","volume":"29","author":"R Ramakrishnan","year":"2002","unstructured":"Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn. 2002;29(1):1\u201324.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2218_CR21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/9780470249031.ch35","volume-title":"Pre-clinical development handbook: ADME and biopharmaceutical properties","author":"HJ Clewell","year":"2008","unstructured":"Clewell HJ, Reddy MB, Lave T, Andersen ME. Physiologically based pharmacokinetic modelling. In: Gad SC, editor. Pre-clinical development handbook: ADME and biopharmaceutical properties. Hoboken: John Wiley & Sons, Inc.; 2008. p. 1167\u2013227."},{"issue":"4","key":"2218_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1089\/jamp.2015.1253","volume":"29","author":"M Caniga","year":"2016","unstructured":"Caniga M, Cabal A, Mehta K, Ross DS, Gil MA, Woodhouse JD, et al. Preclinical experimental and mathematical approaches for assessing effective doses of inhaled drugs, using mometasone to support human dose predictions. J Aerosol Med Pulm Drug Deliv. 2016;29(4):362\u201377.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"4","key":"2218_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/psp4.12074","volume":"5","author":"E Boger","year":"2016","unstructured":"Boger E, Evans N, Chappell M, Lundqvist A, Ewing P, Wigenborg A, et al. Systems pharmacology approach for prediction of pulmonary and systemic pharmacokinetics and receptor occupancy of inhaled drugs. CPT Pharmacometrics Syst Pharmacol. 2016;5(4):201\u201310.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"2218_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bcp.2013.06.026","volume":"87","author":"K Mullane","year":"2014","unstructured":"Mullane K, Williams M. Animal models of asthma: reprise or reboot? Biochem Pharmacol. 2014;87(1):131\u20139.","journal-title":"Biochem Pharmacol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-017-2218-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-017-2218-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-017-2218-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T09:54:50Z","timestamp":1692870890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-017-2218-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2218"],"URL":"https:\/\/doi.org\/10.1007\/s11095-017-2218-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]},"assertion":[{"value":"2 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}